Skip to main content
. Author manuscript; available in PMC: 2022 Aug 1.
Published in final edited form as: Clin Pharmacol Ther. 2021 Apr 19;110(2):380–391. doi: 10.1002/cpt.2240

Figure 6: Effects of sex hormone fluctuations on female TdP classifier predictions.

Figure 6:

A: Receiver operating characteristic curve for female TdP classifier applied on training drugs dataset in absence of hormonal effects (navy blue) or simulating early follicular (EF, azure blue), late follicular (LF, sky blue), and luteal (LU, turquoise) phases. Area under the curve (AUC) is 0.9574, 0.9516, 0.9516, and 0.9505, respectively. B: Rate dependency of biomarkers simulated during different menstrual phases: measurements of voltage- (i) and Ca2+-related (ii-iv) biomarkers as a function of the BCL tested. C: heatmap of the predicted torsadogenic risk probabilities of intermediate TdP risk drugs simulated during different menstrual phases.